REGN Feb 2025 1300.000 call
| Previous close | 61.90 |
| Open | 61.90 |
| Bid | 32.00 |
| Ask | 40.80 |
| Strike | 1,300.00 |
| Expiry date | 2025-02-21 |
| Day's range | 61.90 - 61.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
Insider MonkeyRegeneron Pharmaceuticals, Inc. (REGN): The Best Biotech Stock According to Hedge Funds?
We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1,” the […]
GuruFocus.comInsider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
On September 3, 2024, Arthur Ryan, Director at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), executed a sale of 100 shares of the company at a price of $1178.69 per share. This transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 17,682 shares of Regeneron Pharmaceuticals Inc.
ZacksMerck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
